Semaglutide
FDA-approved GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicine — Ozempic / Wegovy / Rybelsus (each brand has its own approved uses).
Ref $ —reference only
SemaglutideFDA-approved (prescription brands include Ozempic® and Wegovy®)What it's for
FDA-approved GLP-1 (a gut hormone signal for fullness and blood-sugar handling) medicine — Ozempic / Wegovy / Rybelsus (each brand has its own approved uses).
What it's for
Semaglutide is a lab-made peptide that acts like GLP-1, a natural gut hormone signal for fullness and blood-sugar handling that helps the body handle blood sugar and appetite. Brand versions include weekly shots (Ozempic, Wegovy) and a daily tablet (Rybelsus).
What it does for the body
Depending on the brand label, it can help lower blood sugar in type 2 diabetes (Ozempic, Rybelsus), support long-term weight management when obesity or overweight plus other health issues are present (Wegovy), and reduce certain heart risks in people who match the label. The exact approved uses differ by product — they are not automatically interchangeable.
What it targets
It turns on GLP-1 (a gut hormone signal for fullness and blood-sugar handling) receptors (lock-and-key landing spots on cells). That helps the body release insulin when blood sugar is high, lowers a sugar-raising hormone called glucagon, slows how quickly food leaves the stomach, and reduces appetite through gut-to-brain signals. Think of it like turning up a dimmer switch on the body's natural "I'm full / handle sugar after meals" signal.
Research context
Large randomly assigned trials form the backbone of FDA approval (SUSTAIN, STEP, SELECT programs among others). Literature and labels describe study populations by diagnosis (e.g., type 2 diabetes, BMI (body-mass index) thresholds, cardiovascular disease) — those criteria define who was studied, not a personal dose for you. Exact indications differ by brand and formulation. Always check the current FDA label with a clinician.
Studied for (literature interest)
- Type 2 diabetes (blood sugar control) — FDA-approved product labeling
- Chronic weight management with diet and activity — FDA-approved product labeling
- Cardiovascular risk reduction in eligible adults — landmark outcome trials and labeling
- Kidney-related risk reduction in certain people with diabetes and CKD (chronic kidney disease) — labeling expansions
- Additional labeled uses may apply (check current FDA label; overview only)
Cautions (educational)
- Prescription medicine — use only under a licensed clinician and according to the official label.
- Carries important warnings, including a boxed warning about thyroid C-cell tumors seen in rodents.
- This encyclopedia does not provide dosing, titration, or how to obtain any medicine.
- Compounded versions are a separate regulatory topic; FDA has taken enforcement actions related to unapproved GLP-1 (a gut hormone signal for fullness and blood-sugar handling) products.
Citations / starters
- SUSTAIN-6 — Cardiovascular outcomes in type 2 diabetes — Marso et al., N Engl J Med 2016
- STEP 1 — Weight loss in adults with overweight or obesity — Wilding et al., N Engl J Med 2021 · PubMed 33567185
- SELECT — Heart outcomes in obesity without diabetes — Lincoff et al., N Engl J Med 2023
- PubMed search: Semaglutide — NCBI PubMed · literature starter
- ClinicalTrials.gov search: Semaglutide — U.S. clinical trials registry
Reference
No ref on file.